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Abstract
Frequent activation of phosphatidylinositol-3 kinases 
(PI3K)/Akt/mTOR signaling pathway in gastric cancer 
(GC) is gaining immense popularity with identification 
of mutations and/or amplifications of PIK3CA  gene 
or loss of function of PTEN, a tumor suppressor 
protein, to name a few; both playing a crucial role in 
regulating this pathway. These aberrations result in 
dysregulation of this pathway eventually leading to 
gastric oncogenesis, hence, there is a need for targeted 
therapy for more effective anticancer treatment. Several 
inhibitors are currently in either preclinical or clinical 
stages for treatment of solid tumors like GC. With so 
many inhibitors under development, further studies 
PI3K/AKT/MTOR PATHWAY
Several members of PI3K/Akt/mTOR pathway play 
a crucial role in regulating this pathway and hence, 
maintaining cellular homeostasis under normal 
physiological conditions. Some of these essential 
components are described below.
PI3K
PI3K are a family of lipid kinases known to phos­
phorylate the inositol ring of the 3­OH group in inositol 
phospholipids. They are further classified into three 
classes: Class Ⅰ, Ⅱ, and Ⅲ based on primary structure 
and regulation[1]. However, till date only Class Ⅰ, 
assisting in tight regulation of this pathway, has been 
shown to be associated with cancer. Class Ⅰ PI3K is a 
heterodimeric enzyme, with a catalytic and a regulatory 
subunit. The catalytic subunits for class Ⅰ PI3Ks are 
p110α, p110β, p110γ, and p110δ. It is further subdivided 
into class1A, encompassing p110α, p110β, and p110δ 
with a p85α, p85β, and p55γ regulatory subunit, and 
class1B consisting of only p110γ with p101, p84, and 
p87PIKAP regulatory subunits. A typical regulatory 
subunit has several protein­protein interacting 
domains, one of them, the inter­SH2 domain (iSH2) 
interacts with the p110 catalytic subunit, stabilizing 
p110 and its activities[2]. Reports have suggested the 
p110α subunit encoded by the PIK3CA gene as being 
the only catalytic subunit associated with several 
cancers[3]. p110α typically links with p85α, which 
is the most highly expressed regulatory subunit. 
The substrate for class1 PI3K, phosphatidylinositol­




Serine/threonine protein kinase Akt belongs to the 
AGC [named after the protein kinase A, G, and C 
families (PKA, PKC, PKG)] family of kinases. Three 
highly homologous isoforms (Akt1, Akt2, and Akt2) 
of Akt have been identified so far. Structurally, Akt is 
mainly comprised of three domains: an N­terminal 
pleckstrin homology (PH) domain, a central kinase 
catalytic domain (CAT), and a C­terminal extension 
(EXT) containing a regulatory hydrophobic motif (HM). 
Phosphorylation of residues in both the catalytic and 
C­terminal extension domain is essential for complete 
activation of Akt downstream of PI3K signaling. 
PDK1 selectively phosphorylates Thr (308) on the 
CAT domain of Akt, while the kinases responsible for 
phosphorylation of Ser (473) on the EXT domain of 
Akt are still unknown[4]. Thus, phosphorylation of both 
Ser (473) and Thr (308) residues on Akt is required for 
its complete activation[5,6]. Fully activated Akt further 
regulates several processes downstream, along with 
positive regulation of mTOR and thereby mediating 
Singh SS et al . PI3K pathway dysregulation and gastric cancer
12262 November 21, 2015|Volume 21|Issue 43|WJG|www.wjgnet.com
on predictive biomarkers are needed to measure the 
specificity of any therapeutic intervention. Herein, we 
review the common dysregulation of PI3K/Akt/mTOR 
pathway in GC and the various types of single or dual 
pathway inhibitors under development that might have 
a superior role in GC treatment. We also summarize 
the recent developments in identification of predictive 
biomarkers and propose use of predictive biomarkers 
to facilitate more personalized cancer therapy with 
effective PI3K/Akt/mTOR pathway inhibition.
Key words: Epidemiology; Gastric cancer; PI3K/Akt/
mTOR pathway; Predictive biomarkers; Targeted 
therapy
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Core tip: Gastric cancer (GC) is the fifth most common 
cancer in the world with highest incidence rate in 
Eastern Asia and Latin America. With increase in GC 
patient relapse and drug resistance, targeted therapy 
is gaining immense popularity for GC treatment. 
One of the pathways which has been reported to 
be dysregulated is phosphatidylinositol-3 kinases 
(PI3K)/Akt signaling pathway. This review focuses on 
how this pathway is crucial in GC oncogenesis. We 
also summarize the single or dual PI3K/Akt pathway 
inhibitors under investigation for GC treatment. 
Thereby, we discuss the plausible novel biomarkers 
under investigation for a more tailored approach for GC 
treatment.
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INTRODUCTION
The phosphatidylinositol­3 kinases/Akt (PI3K/Akt) 
signaling pathway is activated by several cellular 
stimuli regulating various physiological functions such 
as cell growth, cell survival, cell cycle progression, 
protein translation, and metabolism. Dysregulation 
of this pathway is frequently observed in several 
cancers including gastric cancer (GC). Hence, a 
deeper understanding of this signaling pathway would 
help target this pathway effectively using different 
therapeutic approaches. In this review we will focus 
on how this pathway is regulated in GC and the 
current status of using PI3K/Akt/mammalian target of 
rapamycin (mTOR) targeted therapy for GC treatment.
mTOR activation.
mTOR
The mTOR protein, a 289­kDa serine/threonine 
kinase, is a master regulator of cell growth. It can 
be distinguished into two distinct multi­protein 
complexes; mTOR complex 1 (mTORC1) and mTOR 
complex 2 (mTORC2). The mTORC1 complex is 
composed of mTOR, regulatory­associated protein 
of mTOR (Raptor), mammalian lethal with SEC13 
protein8 (MLST8), PRAS40, and DEPTOR. It functions 
downstream of Akt, integrating the Akt and mTOR 
pathway with 4E­BP1 and S6K, which are immediate 
downstream targets of the mTORC1complex. The 
mTORC2 complex, on the other hand, is composed 
of rapamycin­insensitive companion of mTOR, 
MLST8 and mammalian stress­activated protein 
kinase interacting protein 1. This complex functions 
upstream of Akt/PKB and plays a role in complete 
activation of Akt by phosphorylating Akt at the 
Ser473 residue. Hence, downstream substrates of 
the mTORC2 complex include Akt[7] as well as PKC[8,9]. 
Hence, both complexes are important for effective 
regulation of the Akt/mTOR dual pathway, with the 
mTORC1 complex responsive towards growth factors, 
nutrients, energy, or oxidative stress indirectly while 
the mTORC2 complex plays an important role towards 
Akt activation to assist in complete activation of the 
PI3K/Akt/mTOR pathway.
ACTIVATION MECHANISM
Several receptor tyrosine kinases regulate the 
activation of the PI3K/Akt/mTOR pathway upon 
growth factor stimulation. Growth factors such as 
Insulin growth factor (IGF), epidermal growth factor 
(EGF), and Hepatocyte growth factor activate receptor 
tyrosine kinases (RTKs) via autophosphorylation 
on their tyrosine residues. Lipid kinases, such as 
PI3K, then associate with these phosphorylated 
tyrosine residues to activate the catalytic subunit 
of PI3Ks. For PI3Ks of class1A, the p110α catalytic 
subunit is activated upon p85α associating with 
the RTKs Activated PI3Ks further phosphorylate 
substrates like phosphatidylinositol 4,5­biphosphate to 
phosphatidylinositol 3,4,5­triphosphate (PIP3) within 
a few seconds. Secondary messengers such as PIP3 
further recruit Akt to the membrane by interacting 
with the PH­domain of Akt. Upon membrane tran­
slocation, AKT gets activated by phosphorylation of 
its Ser473 and Thr308 residues by the PDK1 and 
mTORC2 complex respectively. Fully activated Akt 
then regulates several cellular processes by interacting 
with different substrates downstream of Akt. In 
the meanwhile, PTEN, a PIP3 phosphatase, acts a 
regulator of this pathway by maintaining homeostasis 
for this pathway activation. Activated Akt stimulates 
the mTORC1 complex by phosphorylating tuberous 
sclerosis complex2 (TSC2) and PRAS40, which are 
both negative regulators of mTOR. The mTORC1 
complex controls protein translation and cell growth by 
phosphorylating ribosomal S6 kinase and the inhibitory 
partner of the translation initiation factor 4E (4E­BP1), 
which are regulators of protein synthesis[10]. Thus, 
under normal physiological conditions, Akt regulates 
cellular dynamics such as cell growth, cytoskeletal 
reorganization, cell cycle progression, cell survival, 
cell proliferation, protein translation, and cellular 
metabolism by interacting with various substrates, 
which will now be discussed in more detail.
CELLULAR ROLE OF THE AKT/mTOR 
PATHWAY
Cell survival and cell cycle progression
Akt acts as a central regulator of cell survival by 
interacting with anti­apoptotic signals both transcrip­
tionally and post translationally. Akt phosphorylates 
Bad, a Bcl­2 family of anti­apoptotic proteins at 
Ser­136 and Caspase­9, a protease at Ser­196, 
thereby partially blocking cell death and supporting 
cell survival signals. Akt also regulates anti­apoptotic 
functions transcriptionally by translocating into 
the nucleus and regulating the transcription of the 
forkhead box O (FoxO) family of transcription factors. 
The FoxO family of transcription factors regulate cell 
death signals via expression of various members of 
both intrinsic and extrinsic modes of apoptosis as well 
as cyclin­dependent kinase inhibitors. Upon nuclear 
translocation, Akt represses the transcription of FoxO1, 
FoxO3, and FoxO4, thereby enhancing cell survival 
signals[11].
Akt also plays an important role in regulating cell 
cycle progression in normal cells. It either directly 
phosphorylates or indirectly regulates the protein 
expression levels of several molecules of cell cycle 
progression at the G1/S and G2/M phase of the cell 
cycle. These substrates are mentioned in Table 1. 
Cellular metabolism and protein synthesis
Cellular metabolism of carbohydrates into proteins, 
nucleotides, and lipids is a fundamental aspect of 
cell growth and proliferation, with nutrients acting 
as a fuel for cell growth. mTOR plays a crucial role 
in regulating this metabolism in response to nutrient 
availability. Of the two mTOR complexes, the mTORC1 
complex plays a key role in regulating cellular 
metabolism[12]. It receives signals of activation from 
nutrients and growth factors. For example, during 
metabolism of carbohydrates, there is a spike in 
insulin levels, which activates the mTORC1 complex 
of the Akt/mTOR pathway via inhibition of the TSC1/2 
complex by phosphorylation of TSC2 at multiple sites 
to inhibit TSC1[13]. In this process, eventually Ras 
homolog enriched in brain (Rheb), a small GTPase 
belonging to the Ras family of guanine­nucleotide 
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Table 1  Role of Akt in regulating cell cycle
Cell cycle regulation by Akt upon mitogen stimulation
Cell cycle phase Direct regulation Indirect regulation Downstream effect
G1 → S phase P-p21 at Thr145 residue[107] ↑ Transcription of c-MYC[108] Increase in CyclinD expression
Decrease in cdk inhibitors: p21cip1, p21kip1, p15INK4B
G2 → M phase P-Cdc25B at Ser353[109] Cdc-25B inactivation
Cyclin B activation
P-Wee1Hu at Ser642[110] Inactivation of Wee1Hu results in G2/M cell cycle progression
P-Myt1 at Ser75[111] Activation of Cyclin B-associated Cdk1 kinase activity
S → G2 phase P-Cdk2 at Thr39[112] Cytoplasmic shuttling of Cdk2
deregulation in GC[23]. This PIK3CA amplification was 
also associated with poor prognosis of GC patients.
PTEN (Phosphatase and tensin homolog), a 
tumor suppressor of the PI3K/Akt/mTOR pathway 
is frequently mutated or abnormally expressed in 
GC, with eventual functional inactivation of this gene 
product. Its inactivation is associated with increased 
progression towards gastric tumorigenesis. This 
inactivation is attributed to many possible mechanisms. 
While PTEN gene mutations are a rare phenomenon 
of PTEN inactivation, loss of heterozygosity of PTEN is 
more common in GC[24,25]. Abnormal PTEN promoter 
hypermethylation at the CpG islands also inhibits 
PTEN expression in GC tissues[26]. Post­transcriptional 
repression of PTEN by microRNAs is another well 
studied mechanism of PTEN repression in GC. miR21 
and miR­221/222 have been identified as PTEN 
targets repressing PTEN expression by complexing 
with its 3’­UTR region[27­29]. PTEN also undergoes post­
translational modifications like phosphorylation for its 
regulation. A recent study indicated that increased 
phosphorylation of PTEN at the Ser380 residue and 
reduced expression of PTEN could contribute to PTEN 
inactivation in gastric tumor tissues[30]. Overall, PTEN 
inactivation has several functional consequences that 
fall in the category of hallmarks of cancer, such as 
angiogenesis and evading apoptosis. PTEN has been 
shown to elevate the apoptotic cascade via Fas/FasL 
or cytochrome­c mediated activation of capsase­3 
under normal physiological functions. Hence, with 
PTEN inactivation in GC cells, bypassing apoptosis via 
dysregulation of the apoptotic cascade will result in 
“evading apoptosis”, a hallmark of cancer[31,32]. PTEN is 
also known to be a negative modulator of endogenous 
VEGF­mediated signaling. Thus, PTEN inactivation 
is associated with increased VEGF expression, and 
thereby potentiating angiogenesis in GC cells[33]. PTEN 
inactivation also results in constitutive activation of Akt, 
a PKB kinase regulating cell growth, cell death, and 
cell cycle. Using gastric tumor specimens, there has 
been a statistically significant correlation demonstrated 
between increased phosphorylation of Akt with poor 
prognosis of GC patients[34­36]. Functionally, this 
constitutive expression of phosphorylated Akt further 
contributes towards hallmarks of cancer such as 
binding proteins that enhances apoptotic signalling 
at cellular levels[14], is inhibited upon TSC1 complex 
inactivation. The mTORC1 complex is also stimulated 
in the presence of amino acids by promoting the 
conversion of Ras­related GTP­binding protein (RAG) 
heterodimers (RAGA or RAGB, and RAGC or RAGD) 
into their active conformation, which further assists 
in mTORC1 complex cellular localization from the 
cytoplasm to the surface of the lysosome where it 
binds to inactivated RHEB[15­17]. The activated mTORC1 
complex also tightly regulates pathways such as the 
AMP­activated protein kinase (AMPK) pathway by 
preventing its activation in the presence of a high 
ATP/AMP ratio. However, in the absence of energy in 
cells, AMPK gets activated by phosphorylating TSC2 
at Ser1387 and Raptor from the mTORC1 complex 
at Ser­792, resulting in mTORC1 inactivation[18,19]. 
After mTORC1 activation and subsequent complete 
activation of the Akt/mTOR pathway, immediate 
downstream substrates of mTORC1 complex such as 
S6K (ribosomal S6 kinase), 4E­BP1, and ULK1 (UNC­51 
like kinase) are phosphorylated at different residues. 
Interestingly, activated S6K further phosphorylates 
Insulin receptor substrate­1 (IRS­1), upstream of 
mTORC1. Phosphorylation of IRS­1 at serine residues 
by S6 kinases prevents IRS­1 functions and thereby 
PI3K activation[20]. This negative feedback loop of 
the PI3K/Akt/mTOR pathway is an important aspect 
of maintaining homeostasis in cellular metabolism, 
protein synthesis, and cell growth. 
ONCOGENIC POTENTIAL OF PI3K/AKT/
mTOR PATHWAY IN GC
Dysregulations caused by genetic alterations of the 
PI3K/Akt/mTOR pathway have been recently identified 
to play a crucial role in gastric oncogenesis. GC is the 
second most common cause of cancer­related death 
worldwide. PIK3CA, the gene encoding the catalytic 
subunit p110 of PI3K, is frequently mutated in gastric 
carcinoma cell lines and tumor tissues. Some reports 
identify mismatch repair deficiency as one of the 
factors contributing towards the PIK3CA mutations[21­23]. 
Another study suggested PIK3CA amplifications 
contributing towards the PI3K/Akt/mTOR pathway 
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escaping cellular death pathways, cell cycle inhibition, 
and promoting survival and angiogenesis. One of 
the immediate downstream substrates of Akt is the 
FoxO family of transcription factors, which promotes 
growth inhibitory or/and pro­apoptotic signals by either 
regulating cell cycle inhibitory proteins such as p21KIP1 
or p27WAF1/CIP1 or pro­apoptotic proteins of the Bcl­2 
family of proteins[37,38]. Activated Akt phosphorylates 
FoxO and thereby inhibits transcriptional functions of 
this family of proteins, resulting in increased cell survival 
and proliferation[37]. Constitutive phosphorylation of 
FoxO is also correlated with increased expression 
of angiogenesis­related molecules in gastric tumor 
tissues[37]. Akt also directly phosphorylates anti­
apoptotic proteins such as Bad at Ser­136. Thus, GCs 
with increased Akt expression show elevated levels 
of P-Bad at Ser136 that are sufficient to promote cell 
survival[39]. Another important substrate of Akt that 
acts as an initiator of the mitochondrial apoptotic 
pathway is caspase­9. Phosphorylation of capsase­9 at 
Ser-196 results in its inactivation. There is a significant 
correlation between constitutive phosphorylation of Akt 
with caspase­9 phosphorylation in gastric tumor tissues, 
although the mechanism still remains unclear[40]. This 
apoptosis resistance conferred by p­Akt also occurs by 
regulating increased expression of survivin, an inhibitor 
of apoptosis protein with a significant correlation 
between p­Akt and survivin expression levels in gastric 
tumor staging[39]. Pro­survival signals by Akt can also 
be intensified with its interaction with components of 
other signaling pathways such as the NF­κB pathway. 
Akt can phosphorylate NF­κB kinases such as IκB 
kinase (IKKα) at Thr23, resulting in a stimulatory 
phosphorylation and thereby NF­κB activation. This 
further augments the expression of pro­survival signals 
in GC cells[41,42]. Another immediate downstream target 
of Akt is the mTORC1 complex, which is activated by 
phosphorylation of TSC2 by Akt and subsequent TSC1/2 
complex formation, which acts on RHEB (Ras homolog 
enriched in brain) to further phosphorylate mTOR at 
Ser2448 and thereby resulting in mTOR activation. 
Therefore, low expression or mutations in TSC1 are 
associated with a dysfunctional TSC1/2 complex and 
constitutively activated mTOCR1 complex[43]. Recent 
studies have identified high p­mTOR expression to 
be associated with poor prognosis and with some 
clinicopathological characteristics in GC tumor spe­
cimens both independently and in combination with low 
TSC1 expression[44,45]. A preliminary epidemiological 
study identified functional polymorphisms of mTORC1 
contributing towards GC susceptibility in Eastern Chinese 
population[46]. With studies focussing on mTORC1 
complex dysregulation and functional consequences, 
further studies are important to understand mTORC2 
dysregulations, the cause of which still remains unclear. 
Immediate downstream effectors for the activated 
mTORC1 complex are p70S6K and 4E­BP1. p70S6K 
phosphorylation and activation, which mainly occurs in 
the cytoplasm, results in translation of 40s ribosomal 
S6 protein, while phosphorylated 4E­BP1 acts as a 
translational repressor. Recent studies have also shown 
p70S6K and mTOR regulating each other, with p70S6K 
also acting as a kinase for mTOR phosphorylation at 
Ser2448[47]. Aberrant expression of p­p70S6K is linked 
to GC carcinogenesis and its aggressiveness. Nuclear 
localization of this protein could have some inhibitory 
effects towards GC pathogenesis[48].
PRECLINICAL STUDIES AND ONGOING 
CLINICAL TRIALS WITH PI3K/AKT 
INHIBITORS
Involvement of several molecules of the PI3K/Akt/
mTOR pathways in GC carcinogenesis has eventually 
led to development of both single, as well as recently, 
dual inhibitors essential for molecular targeted therapy 
for GC.
PI3K inhibitors and GC
PI3K inhibitors are classified into three classes based 
on their selectivity for the ATP­binding cleft on PI3K 
and pharmacokinetic properties: pan­class Ⅰ, isoform­
selective, and dual PI3K/mTOR inhibitors[49,50].
Pan-Class Ⅰ inhibitors
Pan­class Ⅰ inhibitors have inhibitory effects against each 
isoform of p110 (PIK3CA). Several pan­class Ⅰ inhibitors 
are under investigation for GC targeted therapy, since 
PIK3CA gene mutations comprise 25% of gastric 
tumors, resulting in PI3K dysregulation in GC[51]. 
The first report of a molecular agent inhibiting PI3K 
was quecertin, which was, however, a non­specific 
kinase inhibitor[52]. Eventually, more specific pan­
class Ⅰ inhibitors were identified, such as Wortmannin 
and a quecertin analogue, LY294002. Although 
both LY294002 and Wortmannin exhibited potent 
PI3K­inhibitory properties, there were considerable 
limitations for them to proceed towards clinical 
trials[52­54]. LY294002 showed non­specific targeting, 
a short half­life, and toxicity in vivo[55,56], while Wort­
mannin had limitations involving biological stability and 
short half­life[57].
To further improve on the pharmacological avail­
abilities, a structural analogue of Wortmannin, PX­866 
was developed.
PX-866: PX­866 is a semisynthetic pan­class­1, 
Wortmannin analogue with inhibitory concentrations 
in nanomolar ranges and better efficacy and a safer 
pharmacokinetic profile than Wortmannin. Pre­
clinical in vivo studies have shown its anti­cancer 
effect against several xenograft models of various 
cancers[57,58]. It is currently in Phase Ⅱ clinical trials 
for patients with glioblastoma and head and neck 
cancer[59,60].
12265 November 21, 2015|Volume 21|Issue 43|WJG|www.wjgnet.com
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PX­866 recently also came under limelight for a 
multicenter trial for advanced solid tumors including 
gastric tumors. Data from the trial show that PX­866 
can be administered with endurable toxicity for 
patients with advanced solid tumors[61].
NVP-BKM120 (Buparlisib): NVP­BKM120 is a potent 
pan­class Ⅰ PI3K inhibitor with its activity in nanomolar 
ranges for all the isoforms of Class Ⅰ PI3K. Preclinical 
investigations have revealed its effectiveness in a 
diverse range of cancer cell lines, with increased 
sensitivity in tumors harboring PIK3CA mutations[62]. 
Similar results were also observed in a panel of GC 
cell lines[63]. Additionally, combination therapy using 
PI3K and STAT3 inhibitors showed better efficacy and 
a synergistic effect in GC cell lines harboring KRAS 
mutations. The STAT3 pathway is also known to be 
constitutively activated in GC[64]. Although preclinical 
studies on BKM120 in GC are still ongoing, it has 
reached Phase Ⅱ clinical trials for other cancers such 
as brain, breast, colorectal, endometrial, NSCLC, 
and renal cell carcinoma[49,65­67]. Thus, BKM120 has a 
potential to progress into clinical trials for GC treatment 
using targeted therapy.
ZSTK474: ZSTK474, a pan­class 1 PI3K inhibitor 
inhibits all the four isoforms of PI3K and exhibits anti­
tumor activity in vivo against human tumor xenograft 
models[68­70]. In vitro studies in GC cell lines suggest 
combination therapy of ZST474 and IGFR inhibitors 
for treating IGFR­positive cancers to overcome any 
intrinsic resistance to inhibition of PI3K/Akt/mTOR 
signaling, since over­expression of IGFR correlated 
with increased tyrosine phosphorylation on Insulin 
Receptor substrate, leading to increased PI3K activation. 
Hence, combination therapy with both ZST474 and 
IGFR inhibitors on GC cells with high IGFR expression 
exerted a superior therapeutic response[71].
BAY80-6946: BAY80­6946 is synthesized by Bayer 
healthcare and is a highly potent, selective, and 
reversible pan­class Ⅰ inhibitor working in nanomolar 
concentrations against all the isoforms of p110. 
However, it shows preferential activity against p110α 
and β than p110 γ and δ in tumor cell lines and 
xenograft models[72]. BAY80­6946 demonstrated 
acceptable safety profiles in phase Ⅰ clinical trials for 
advanced solid tumors, and therefore, exhibiting a 
potential to be progressed to phase Ⅱ clinical trials for 
patients with advanced solid tumors.
Isoform specific PI3K inhibitors
PI3K isoform specific inhibitors were designed with 
an aim to provide comparable or superior efficacy 
than pan­class Ⅰ inhibitors. Some of them under 
investigation for GC treatment will now be discussed.
BYL719: BYL719 is an α-isoform specific PI3K inhibitor 
working at nanomolar concentrations with minimal 
activity against other PI3K isoforms[73]. With the PI3K/
Akt/mTOR pathway being frequently dysregulated in 
GC, BYL719 exhibited its inhibitory effects in synergy 
with another inhibitor LJM716, a ligand dependent as 
well as independent HER3 inhibitor, in GC xenograft 
models[74]. Interestingly, the combination study was 
done in HER2 positive GC cell lines, suggesting the 
sensitivity of this drug towards HER amplifications. 
BYL719 also recently completed Phase1b clinical trial 
for advanced stage GC in a combinational study with 
the HSP90 inhibitor AUY922 in patients whose tumors 
either harbour molecular alterations of PIK3CA or 
HER2 amplification[75].
INK1117: INK117 is another novel, selective p110α 
inhibitor. It is particularly more effective and sensitive 
to tumors bearing PIK3CA mutations. With good oral 
bioavailability in preclinical xenograft studies, it has 
entered a phase­Ⅰ study for advanced solid tumors 
including GC, to evaluate its safety, tolerability, 
pharmacokinetic and pharmacodynamic properties[76].
Dual PI3K/mTOR inhibitors
PI3K/mTOR dual inhibitors inhibit PI3K and the 
downstream mTOR kinase activity by binding to 
the ATP­binding cleft of these enzymes. Relative to 
the single inhibitors, these drugs have the benefit 
of inhibiting mTORC1 and mTOCR2, as well as all 
the isoforms of PI3K. Evidence has suggested that 
the mTORC1/S6K axis has a “two­edge sword”­like 
function in activation of the PI3K/mTOR pathway by 
promoting growth signals downstream of Akt, as well 
as mediating a potent negative feedback loop that 
restrains signaling via the insulin/IGFR and other 
RTKs. Dysregulation of this negative feedback loop 
has been reported to contribute towards resistance 
in cancers subjected to single inhibitors[77]. Hence, 
the need of dual PI3K/mTOR inhibitors arises with 
an aim to discover drugs with low toxicity and good 
pharmacokinetic profile.
NVP-BEZ235: NVP­BEZ235 is a novel dual ATP­
competitive PI3K and mTOR inhibitor for p110α/β/γ/δ 
and mTOR kinase, with inhibitory doses at nanomolar 
ranges. It first entered phase trials for breast cancer[78]. 
The effectiveness of BEZ235 has been investigated 
in both PIK3CA mutated and wild type cell lines in 
vitro and in xenograft models in vivo. The first group 
reporting an effect of BEZ235 on gastric xenografts 
showed reduced tumor growth for NCI­N87 but not 
MKN­45 or MKN­28 xenografts. Interestingly, the 
reduction in tumor growth correlated with thymidine 
kinase expression and not PI3K/mTOR pathway 
inhibition[79]. Another group demonstrated in vitro 
increased sensitivity of AGS, PIK3CA mutated cells 
than for NCI­N87 and MKN­45, wild type PIK3CA GC 
cells[63]. Clinically, the response rate for BEZ235 was 
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highest for patients with PIK3CA mutations than those 
without this mutation[80]. However, another recent 
study showed an increased anti­tumor response with 
BEZ235 alone or in combination with nab­paclitaxel 
in NCI­N87, AGS, and SNU­16 GC cells, independent 
of PIK3CA mutation status in vitro and in a SNU16 
xenograft model in vivo[81]. Hence, with increasing 
preclinical studies focusing on using NVP­BEZ235 for 
GC targeted therapy, and its gaining popularity in 
clinical trials for other cancers, NVP­BEZ235 might be 
a good potential candidate drug to be considered for 
clinical trials for solid tumors such as GC.
VS-5884: VS­5884 is a dual PI3K and mTOR inhibitor, 
inhibiting all the isoforms of PI3K and both mTOR 
complexes (mTORC1 and mTORC2), with nanomolar 
inhibitory concentrations for a panel of cancer cell 
lines in vitro and increased sensitivity towards cell 
lines harboring PIK3CA mutations. It also exhibits a 
favourable pharmacokinetic profile in vivo. VS­5884 
shows a statistically significant inhibition of tumor 
growth in HER­over­expressing GC xenograft models 
(NCI­N87). This drug also exhibits a synergistic 
response in these xenograft models with geftinib, an 
EGFR inhibitor (EGFRi), currently in phase Ⅱ trials for 
GC treatment. Since this drug has proven its efficacy 
for monotherapy and combination therapy in GC 
xenograft models[82], these data provide a rationale 
for testing VS­5884 in early phase clinical trials for GC 
patients.
PI-103: PI­103 is an ATP­competitive PI3K and 
mTOR inhibitor with variable sensitivities towards 
different isoforms of p110 and mTOR at nanomolar 
concentrations. It was recently assessed for its 
synergistic effect to enhance the anti­tumor response 
for GC both in vitro and in vivo with 5­FU treatment. 
This study suggested PI­103 usage for enhancing 5­FU 
chemotherapy for GC; with 5­FU currently being used 
to treat GC patients but demonstrating limitations due 
to inter­variability in response rate of these patients. 
This synergistic effect of PI­103 with 5­FU was also 
associated with PIK3CA mutations and reduction of 
downstream effectors of PI3K/Akt/mTOR pathway 
and thymidylate synthase, an enzyme that generates 
thymidylate precursors for DNA synthesis in vitro[83].
Akt inhibitors and GC
The Akt signaling cascade controls a spectrum of 
tumorigenesis events such as cell growth, proliferation, 
survival, angiogenesis, invasion, and metastasis, as 
well as activation of the mTOR signaling cascade. 
Several mutations or amplifications in the Akt/mTOR 
signaling cascade contribute towards constitutive 
activation of Akt, which includes PTEN mutations 
and PIK3CA mutations, as well as over­expression/
amplification of Akt itself[84­87]. With activated Akt 
playing a crucial role in tumorigenesis, several Akt 
inhibitors have been designed that have entered 
preclinical as well as clinical trials. Akt inhibitors that 
are currently being investigated for GC treatment 
include:
AZD5363: AZD5363 binds to and inhibits all the 
isoforms of Akt (Akt1, Akt2, and Akt3) with potency 
in the nanomolar range. Reports have suggested 
increased sensitivity towards AZD5363 in cancer 
cells harboring PIK3CA mutations, PTEN mutations, 
or HER­2 amplifications both in vitro and in vivo[88]. 
This sensitivity of AZD5363 towards the activating 
mutations was also tested in GC xenograft models, one 
with a PIK3CA mutation and another with PTEN loss. 
AZD5363 exhibited a relatively more significant anti-
tumor response towards PIK3CA mutant GC xenografts 
than those with PTEN loss alone. Interestingly, for 
GC xenografts with inactivated PTEN treated with a 
combination of AZ5363 and taxotrene, a synergistic 
and potent anti­tumor response was observed rather 
than monotherapy with AZD5363[89]. Hence, selection 
of patients based on their mutational status would be 
beneficial for targeted therapy, which can eventually 
lead to more effective and tailored therapy either with 
single agents or in combination.
MK-2206: MK­2206 is a highly selective, allosteric 
Akt inhibitor, with higher potency for Akt1 and Akt2 
isoforms than Akt3. Its efficacy was investigated both 
in vitro and in vivo as a single agent as well as in 
combination with several chemotherapeutic drugs or 
molecular targeted drugs (EGFRi) to overcome any 
potential resistance. This drug enhances the anti­
tumor response in combination therapy, making it a 
suitable and promising agent for the second line of 
therapy in cancer patients receiving chemotherapy 
or targeted therapy[90]. This drug is currently used in 
phase Ⅱ trials as a second­line therapy for gastric and 
gastroesophageal cancer[91].
Perifosine: An oral anti­cancer agent and an Akt 
inhibitor, Perifosine has entered clinical trials for major 
human cancers. eIF4E is a downstream effector 
of the Akt/mTOR pathway, and increased levels of 
phosphorylated eIF4E and total­eIF4E correlate with 
increased GC in tumor tissues. A recent study showed 
that Perifosine treatment of GC cells with increased 
eIF4E expression (p­eIF4E) down­regulated eIF4E 
expression, and thereby exerting an inhibitory effect 
on the Akt/mTOR pathway. Also, the combination 
of eIF4E inhibitor with Perifosine in these GC cells 
further sensitized the cells towards more effective 
treatment[92]. Another study of combination therapy 
in GC revealed the effectiveness of Perifosine in 
combination with a miR­27a inhibitor, an oncogene 
that contributes to drug resistance in GC cells[93]. With 
more studies identifying the molecular mechanisms 
of Perifosine inhibition in GC, a recent study shows 
Perifosine inhibiting tumor growth in GC cells via 
inhibition of the Akt/GSK3β/C­MYC signaling pathway, 
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with significant down­regulation of AEG­1 (Astrocyte 
elevated gene), a gene reported to play an important 
role in cellular processes such as proliferation, 
apoptosis, and invasion[94]. Hence, Perifosine is a 
good potential therapeutic Akt inhibitor when used in 
combination therapies to overcome drug resistance, 
with scope for further progression into clinical trials.
TCN-PM: Triciribine Phosphate Monohydrate (TCN­PM) 
is a potent Akt inhibitor inhibiting all the three isoforms 
of Akt. In Phase Ⅰ studies of patients with solid 
tumors, where TCN­PM was administered to patients 
with increased p­Akt levels (as assessed by immuno­
histochemical staining), a moderate reduction in p­Akt 
was observed after single TCN­PM therapy, which may 
have been possibly due to a small sample size. Further 
studies to confirm its availability as a single agent as 
well as its efficacy in combination treatments would 
help to promote its importance for phase Ⅱ clinical 
trials for GC[95].
mTOR inhibitors
mTOR is often dysregulated in GC, with several 
preclinical studies suggesting mTOR as a potential 
therapeutic target. mTOR forms two types of com­
plexes to perform its cellular function based on its 
interacting partner and substrate specificity, these 
being the mTORC1 and mTOR2 complex. The mTORC1 
complex is rapamycin sensitive[96]; rapamycin being 
the first mTOR inhibitor developed, while the mTORC2 
complex is rapamycin insensitive. mTOR inhibitors are 
classified into two types based on their specificity for 
mTOR complexes: Rapalogs and mTORC1/2 inhibitors.
Rapalogs: Rapamycin and its analogs (referred as 
rapalogs), first form a complex with the intracellular 
receptor FK506 binding protein 12 (FKBP12) and 
then bind to a domain separate from the catalytic site 
of mTOR, preventing mTOR function. Rapalogs are 
effective against the mTOCR1 complex[97]. Some of the 
rapalogs under preclinical and clinical studies for GC 
treatment are as follows:
Temsirolimus: Temsirolimus binds to FKBP12, 
and the resultant protein­drug complex prevents 
mTORC1 activity. A Phase Ⅰ clinical study determined 
a favorable toxicity profile, maximum tolerated dose, 
pharmacokinetics, and anti-tumor efficacy in patients 
with advanced cancer including GC, making it a 
favorable drug to proceed towards phase Ⅱ trials[98].
Everolimus ­ Everolimus is another oral mTORC1 
complex inhibitor that has demonstrated good safety 
and clinical tolerability profile in Phase Ⅰ trials for 
several cancers including GC. Phase Ⅱ trials for 
patients with advanced GC treated with Everolimus 
exhibited a good median progression free survival 
(PFS). Phase Ⅲ trials for previously treated GC did 
not show a significant overall survival benefit vs best 
supportive care patients. However, the PFS for six­
months and the safety profile was significant, which 
highlights the need for predictive biomarkers for 
Everolimus treatment response in order to obtain 
better efficacy for this drug[99].
Ridaforolimus: Ridaforolimus, a rapamycin analog, 
is under clinical investigation with its well defined 
anti­tumor response in preclinical studies. It showed 
a synergistic anti­tumor response in patients with 
solid tumors including GC, in a Phase Ib trial, where 
ridaforolimus was given in combination with capecitabine, 
a prodrug that converts into FU[100].
mTORC1/2 inhibitors
Although mTORC1 inhibition by rapamycin analogs 
results in substantial tumor growth inhibition, drug 
resistance has been reported due to a negative 
feedback loop in the PI3K/Akt/mTOR pathway either 
via RTKs upregulation with increased Akt activation 
or crosstalk of PI3K with Ras signaling, leading to 
MAPK pathway activation. Hence, mTORC1/2 complex 
inhibitors have gained interest owing to their ability 
to act as ATP­competitive inhibitors of mTOR kinase 
activity.
PP242: PP242 significantly inhibits mTOR kinase 
activity, inhibiting both mTORC1 and mTORC2 complex 
activities. It shows superior anti­proliferative and anti­
angiogenesis effects in GC cell lines in vitro relative 
to rapamycin, indicating its promising potential as a 
therapeutic drug in future for GC[101].
Other mTORC1/2 inhibitors that have been under 
investigation for solid tumor treatment include AZD2014, 
AZD8055, and OSI­027; however, there are currently 
no reports on their usage for GC treatment.
POTENTIAL BIOMARKERS FOR 
TARGETED THERAPY
The PI3k/Akt/mTOR pathway is activated in approxi­
mately 30%­60% of GC tumors. Hence, targeted therapy 
using either single or dual Akt/mTOR inhibitors is under 
investigation in several clinical trials as summarized in 
Table 2, with Everolimus, an mTOR inhibitor, being the 
only drug to date that has progressed towards phase 
Ⅲ trials for advanced GC patients[99]. Unfortunately, 
overall survival (OS) for GC patients treated with 
Everolimus was not significant; hence, identification of 
specific biomarkers for patient selection for Everolimus 
treatment would aid in more personalized therapy, 
with a potential for better efficacy and anti­tumor 
response. Although Everolimus failed to significantly 
improve the overall survival of patients with refractory 
advanced gastric cancer (AGC), an interesting case 
study showed satisfactory Everolimus monotherapy 
in a patient with refractory AGC harboring PIK3CA 
mutations and pS6 aberrations[102]; indicating the 
12268 November 21, 2015|Volume 21|Issue 43|WJG|www.wjgnet.com
Singh SS et al . PI3K pathway dysregulation and gastric cancer
importance of predictive biomarkers for various 
subpopulations of AGC for effective treatment. With 
studies ongoing for biomarker discovery for better 
prognosis with Everolimus treatment for AGC patients, 
some biomarkers that have been explored to predict 
Everolimus sensitivity in other cancers are PIK3CA/
PTEN genomic aberrations[103,104].
With the lack of predictive biomarkers, the need 
arises to discover new molecules as surrogate markers 
to further segregate the AGC patient population for 
more efficient PI3K/Akt/mTOR pathway inhibition. 
Recent reports have also shown constitutive activation 
of the Akt/mTOR pathway being regulated by receptor 
interacting protein­1 (RIP1), a key enzyme in the 
activation of survival pathways such as Akt/mTOR 
as well as NF­κB[105]. RIP­1 down­regulates PTEN 
expression as well as suppresses the mTOR/PI3K 
feedback inhibitory loop, leading to potent activation 
of this pathway. At the same time, RIP1 also mediates 
activation of NF­κB pathway, where TAK­1 (TGF­β), a 
key regulator of the signaling cascade, is recruited to 
the TNF­α receptor complex, which is a pivotal step 
for IKK (IκB kinase) activation. The NF­κB pathway is 
aberrantly activated in several cancers including breast 
and GC, and recently, an oncogene DP103 (a DEAD­
box RNA helicase), was identified by our group to 
be upregulated in breast, prostate, gastric and colon 
cancers, and was shown to define the metastatic 
potential via activation of the NF­κB pathway in 
two independent breast cancer cohorts[106]. DP103 
regulates the NF­κB pathway via direct interaction 
with TAK1 and thus, the DP103­TAK1 protein complex 
regulates activation of NF­κB in breast cancer[106]. With 
TAK1 activation also being RIP­1 dependent, cross talk 
between the Akt/mTOR and NF­κB pathways suggests 
exploring the role of DP103 as a future biomarker for 
GC upon aberrant PI3K/Akt/mTOR pathway activation.
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